CD274 and non-small cell lung carcinoma: As we reviewed above, available data indicate that the addition of ICIs to chemotherapy with or without an anti-angiogenic agent increases survival benefits in advanced NSCLC, regardless of PD-L1 expression proportions [16,17,18,19,23,32,34].